Once-weekly somapacitan versus daily GH in children with GH deficiency: Results from a randomized phase 2 trial.

CONCLUSIONS: In children with GHD, once-weekly somapacitan 0.16mg/kg/week provided the closest efficacy match with similar safety and tolerability to daily GH after 26 and 52 weeks of treatment.
PMID: 31917835 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - January 8, 2020 Category: Endocrinology Authors: Sävendahl L, Battelino T, Brod M, Rasmussen MH, Horikawa R, Juul RV, Saenger P Tags: J Clin Endocrinol Metab Source Type: research